突发！一公募基金暂停大额申购

Group 1 - The core announcement is that the China Europe Medical Innovation Equity Fund will restrict subscription, conversion, and regular investment amounts starting from August 11, 2025, to ensure stable operation and protect the interests of fund shareholders [1][2]. - The maximum amount for a single or cumulative subscription, conversion, or regular investment for any category of fund shares is set at 100,000 yuan [1][2]. - The fund, established in February 2019 and managed by Ge Lan, primarily invests in stocks related to the medical innovation sector, aiming to achieve returns that exceed the performance benchmark while strictly controlling investment portfolio risks [2][3]. Group 2 - As of the end of the first half of the year, the fund's top ten holdings include companies such as Sangfor Technologies, Kelun-Botai Biotech, and WuXi Biologics [3]. - The fund's main code is 006228, and it has two sub-funds: China Europe Medical Innovation Stock A (006229) and China Europe Medical Innovation Stock C [2]. - The fund's management company is China Europe Fund Management Co., Ltd., which is responsible for the fund's operations and compliance with relevant regulations [2].